Edit this postArtemis Medicare: Buy Call with Strong Expansion and Growth Outlook
Choice Equity Broking Recommends Buy
Target: ₹325 | CMP: ₹251.15
Artemis Medicare Services Ltd’s flagship Gurgaon hospital achieved the highest Average Revenue Per Occupied Bed (ARPOB) of ₹83,900 in Q1FY26, driven by advanced clinical offerings such as robotic surgery and Cyberknife. The company’s focus on specialized healthcare continues to deliver strong operational performance.
Currently operating 700 beds, Artemis plans to add 120 more in Gurgaon and 600 across Raipur and South Delhi, aiming for 1,700 beds by FY29. The expansion marks a major step toward multi-city healthcare leadership.
Growth and Financials
With a projected CAGR of 26%/30%/31% in Revenue/EBITDA/PAT over FY25–28, Artemis is positioned for multi-year compounding. The new tie-up with VIMHANS expands its reach into mental health while maintaining high occupancy across existing facilities.
The company trades at a PEG ratio of 1.07, indicating fair valuation compared to peers. Analysts see further upside as Artemis benefits from its premium positioning and regional diversification.
Analysts highlight that new capex in NCR and Tier-2 cities may dilute EPS by 15% in the short term but strengthens long-term scalability and brand presence.
👉 Nifty Tip | BankNifty Tip
Investor Takeaway
Artemis Medicare remains a quality pick in the healthcare space, backed by robust financials, expanding footprint, and strong demand visibility. Investors may consider accumulating for medium-term growth potential.
Nifty and Bank Nifty Expert Gulshan Khera, CFP®, who is a SEBI Regd Investment Adviser.
Find more expert analysis at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
